Incision-Free Ablative Intervention With Vision TULSA – A real-time imaging guided therapy platform for ablation of prostate tissue malignant or benign Corporate Presentation | May 2025 © 2025 Profound Medical Corp. NASDAQ: PROF, TSX: PRN 1 • FDA cleared in August 2019; first commercial site in January 2020, AI assistant cleared in May 2024 • Using patient cash pay business model installed >50 sites, >3,000 patients treated • New reimbursement codes established by AMA, placed by CMS in urology Level 7, effe ...

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that the first commercial benign prostatic hyperplasia ("BPH") treatment utilizing the TULSA-PRO system's new TULSA-AI Volume Reduction Module was successfully conducted yesterday by Naveen Kella, M.D., Founder of ...

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it has entered into a consulting agreement with Leonard Wheeler, a former NFL player turned entrepreneur, author, corporate consultant, co-Executive Director of the NFL Legends Community, and more recently, na ...

TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company’s management information ...

Profound Medical Corporation (NASDAQ:PROF) Q1 2025 - Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Stephen Kilmer - Head IR Rashed Dewan - CFO Dr. Mathieu Burtnyk - COO Tom Tamberrino - Chief Commercial Officer Arun Menawat - CEO Conference Call Participants Ben Haynor - Lake Street Capital Markets John McAuley - Stifel Michael Freeman - Raymond James Scott McAuley - Paradigm Capital Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter 2025 F ...

Profound Medical (PROF) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -24.14%. A quarter ago, it was expected that this company would post a loss of $0.30 per share when it actually produced a loss of $0.20, delivering a surprise of 33.33%.Over the last four quarters, the company has surpas ...

Profound Medical (PROF) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Stephen Kilmer - Investor RelationsRashed Dewan - CFOMathieu Burtnyk - PresidentTom Tamberrino - Chief Commercial OfficerArun Menawat - Chairman & CEOBen Haynor - Managing DirectorJohn McAulay - AVPScott McAuley - Head of Research Conference Call Participants Michael Freeman - Equity Research Analyst - Healthcare Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter twenty tw ...

Profound Medical (PROF) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Stephen Kilmer - Investor RelationsRashed Dewan - CFOMathieu Burtnyk - PresidentTom Tamberrino - Chief Commercial OfficerArun Menawat - Chairman & CEOBen Haynor - Managing DirectorJohn McAulay - AVPScott McAuley - Head of Research Conference Call Participants Michael Freeman - Equity Research Analyst - Healthcare Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter twenty tw ...

Profound Medical (PROF) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter twenty twenty Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To wit ...

EXHIBIT 99.1 Profound Medical Announces First Quarter 2025 Financial Results TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the first quarter ended March 31, 2025. Unless specified otherwise, all amounts in this press release are expresse ...